DB00841ApprovedInvestigationalSmall moleculeAdrenergic beta-AgonistsSelective Beta 1-adrenergic AgonistsSympathomimetic (Adrenergic) Agents
Dobutamine is a beta-1 agonist used to treat cardiac decompensation in patients with organic heart disease or from cardiac surgery. A beta-1 agonist catecholamine that has cardiac stimulant action without evoking vasoconstriction or tachycardia.
- Mechanism
- Curator reviewed
Dobutamine directly stimulates beta-1 receptors of the heart to increase myocardial contractility and stroke volume, resulting in increased cardiac output.
- Primary indication
- Indicated when parenteral therapy is necessary for inotropic support in the short-term treatment of patients with cardiac decompensation due to depressed contractility resulting either from organic heart disease or from cardiac surgical procedures.Curator reviewed · 4 structured indications
- Formula / weight
- C18H23NO3 · 301.3801 g/mol (avg)
- First approval
- Canada, 2003 · United States, 1993
- Also known as
- DL-dobutamine · rac-dobutamine · racemic-dobutamine
Resolves to
Clinical / RWD
Structure
InChIKey
JRWZLRBJNMZMFE-UHFFFAOYSA-NSMILESCC(CCC1=CC=C(O)C=C1)NCCC1=CC(O)=C(O)C=C1What you can answer from here — as of September 23, 2026
4Protein targetsEach mapped to UniProt, with action and pharmacological actionListed above
Which drugs share a target with Dobutamine, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account